| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5928872 | American Heart Journal | 2013 | 6 Pages |
Abstract
Rosiglitazone adversely affected 3 novel biomarkers and favorably affected a fourth previously associated with atherosclerosis while improving hs-CRP, as has previously been shown. Whether these complex effects on circulating inflammatory biomarkers contribute to the signal of increased MI risk with rosiglitazone and whether pioglitazone has similar effects warrant further investigation.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Elan MD, Andrew W. MD, M. Odette MD, Raphael MD, Shuaib M. MD, MSc, Colby R. MS, Anand MD, Amit MD, MSc, James A. MD, Darren K. MD, MHSc,